Moderna’s Stock Is on a Roll. Now It Has to Deliver a New Booster.
Moderna shares have been on a tear as a rise in Covid-19 cases in the U.S., and the advent of updated vaccine boosters, have built the case that the company can benefit for longer from selling its shots.
“We don’t actually know what will be important in the fall, and there’s no way to know,” says Dr. Eric Rubin, a member of the FDA’s vaccines advisory committee and the editor in chief of the New England Journal of Medicine. “The FDA is sort of rolling the dice on the idea that it might be a better match.”
https://www.marketwatch.com/articles/moderna-stock-vaccine-booster-fda-51657919393